JP2019512020A - がんの治療 - Google Patents

がんの治療 Download PDF

Info

Publication number
JP2019512020A
JP2019512020A JP2018561191A JP2018561191A JP2019512020A JP 2019512020 A JP2019512020 A JP 2019512020A JP 2018561191 A JP2018561191 A JP 2018561191A JP 2018561191 A JP2018561191 A JP 2018561191A JP 2019512020 A JP2019512020 A JP 2019512020A
Authority
JP
Japan
Prior art keywords
days
vaccine
inhibitor
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018561191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512020A5 (enExample
Inventor
マクニール，ダグ
レスニエフスキー，リチャード
Original Assignee
マディソン ヴァクシーンズ インコーポレイテッド
マディソン ヴァクシーンズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マディソン ヴァクシーンズ インコーポレイテッド, マディソン ヴァクシーンズ インコーポレイテッド filed Critical マディソン ヴァクシーンズ インコーポレイテッド
Publication of JP2019512020A publication Critical patent/JP2019512020A/ja
Publication of JP2019512020A5 publication Critical patent/JP2019512020A5/ja
Priority to JP2022064122A priority Critical patent/JP2022088665A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
JP2018561191A 2016-02-12 2017-02-10 がんの治療 Ceased JP2019512020A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022064122A JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US62/294,349 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US62/404,252 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022064122A Division JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Publications (2)

Publication Number Publication Date
JP2019512020A true JP2019512020A (ja) 2019-05-09
JP2019512020A5 JP2019512020A5 (enExample) 2020-03-26

Family

ID=59088211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561191A Ceased JP2019512020A (ja) 2016-02-12 2017-02-10 がんの治療
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Country Status (8)

Country Link
US (5) US11000578B2 (enExample)
EP (1) EP3413927A4 (enExample)
JP (2) JP2019512020A (enExample)
CN (1) CN108883203A (enExample)
AU (1) AU2017217940B2 (enExample)
CA (1) CA3013930C (enExample)
HK (1) HK1258319A1 (enExample)
WO (1) WO2017139628A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
WO2020097209A1 (en) * 2018-11-06 2020-05-14 Wisconsin Alumni Research Foundation Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
AU2020218259A1 (en) * 2019-02-08 2021-09-02 Madison Vaccines Inc. Cancer therapy
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
WO2021108331A1 (en) * 2019-11-26 2021-06-03 The Regents Of The University Of California Combination therapy for head and neck cancer
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118360A1 (en) 2021-12-23 2023-06-29 Universiteit Maastricht Immunoprotective type implantable cell delivery device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7179797B2 (en) 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
WO2009052328A1 (en) 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US20110301052A1 (en) 2010-04-16 2011-12-08 Mcneel Douglas G Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
US8603485B2 (en) 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
NZ701324A (en) * 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2017000857A (es) * 2014-07-18 2017-10-11 Advaxis Inc Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
JP2017535599A (ja) 2014-11-07 2017-11-30 ウィスコンシン アラムニ リサーチ ファンデーション Ｂ細胞標的ｄｎａワクチン
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017139755A1 (en) 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HISTORY OF CHANGES FOR STUDY: NCT02499835[オンライン］,2015.07.29[検索日：2021.11.26］,インターネッ, JPN6021048025, ISSN: 0004656569 *
MOLECULAR CANCER THERAPEUTICS, DEC. 2015, VOL. 14, ISSUE 12, SUPPL. 2, ABSTRACT NO. CN04-03, JPN6021004932, ISSN: 0004444015 *
PD-1/PD-L1 COMBINATION THERAPIES, NOV 2015, HTTP://INFO.EVALUATEGROUP.COM/RS/607-YGS-364/IMAGES/EPV-, JPN6021004933, ISSN: 0004444016 *

Also Published As

Publication number Publication date
US20170182139A1 (en) 2017-06-29
US11000578B2 (en) 2021-05-11
US20250074987A1 (en) 2025-03-06
CA3013930A1 (en) 2017-08-17
HK1258319A1 (zh) 2019-11-08
EP3413927A4 (en) 2019-11-27
CN108883203A (zh) 2018-11-23
JP2022088665A (ja) 2022-06-14
US20190030150A1 (en) 2019-01-31
US20240115684A1 (en) 2024-04-11
AU2017217940B2 (en) 2024-03-21
WO2017139628A1 (en) 2017-08-17
CA3013930C (en) 2025-03-18
US20210283232A1 (en) 2021-09-16
AU2017217940A1 (en) 2018-08-23
EP3413927A1 (en) 2018-12-19
US11806391B2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
US11806391B2 (en) Combinatorial method of treating prostate cancer
US11439697B2 (en) Nant cancer vaccine
US10023841B2 (en) Methods and compositions for treating breast cancer with dendritic cell vaccines
US10597731B2 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
US20180318347A1 (en) Methods for treating cancer
Herbert et al. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
US20220211832A1 (en) Treatment methods
WO2017139755A1 (en) Cancer therapy
CA2874065A1 (en) Methods and compositions for treating breast cancer with dendritic cell vaccines
Knutson et al. A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
US20230034802A1 (en) Nant Cancer Vaccine
US20220133873A1 (en) Cancer therapy
Baurain et al. Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
Gross Therapeutic Vaccinatinon for the Treatment of Metastatic Breast Cancer
Patel PHASE I/II TRIAL OF A LONG PEPTIDE VACCINE (LPV7) PLUS TLR AGONISTS FOR RESECTED STAGE IIB–IV MELANOMA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220407

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220502

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220510

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220527

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20241029